Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder
Schizophrenia and Bipolar Disorder have a significant burden that is expected to have escalated due to COVID-19. People with serious mental illness are at increased risk of COVID-19 and have higher rates of hospitalization, morbidity, and mortality. Drs. Correll and Chen discuss how the pandemic has affected patients with schizophrenia and bipolar disorder, including access to long-acting injectable antipsychotics.
Christoph Correll is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. Maxine Chen is an employee of Otsuka Pharmaceutical …
